Hologic, Inc. (HOLX) and its subsidiary, Biotheranostics, recently presented new research findings. The results suggest that in the absence of Breast Cancer Index (BCI) genetic testing, a significant proportion of early-stage hormone receptor-positive (HR+) breast cancer survivors may have received excessive or insufficient treatment. The study was published in the March issue of the JNCCN — Journal of the National Comprehensive Cancer Network.Previous research has shown that most women with early-stage HR+ ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced newly published study results revealing that use of the Breast Cancer Index® (BCI) test led to physicians changing their long-term anti-estrogen treatment recommendations for 40% of patients with early-stage hormone receptor-positive (HR+) breast cancer.1 The results, which suggest that many women may be over- or undertreated without the incorporation of BCI, reflect real-world data f ...

Hologic (HOLX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this medical device maker have returned +1.7%, compared to the Zacks S&P 500 composite's +4.8% change. During this period, the Zacks Medical - Instruments industry, which Hologic falls in, has gained 4.7%. The key question now is: What could be the stock's future direction?Although media repor ...

mapodile/E+ via Getty Images Shares of Hologic (NASDAQ:HOLX) have been trading relatively stagnant in recent years, while the underlying business has seen quite some volatility since the outset of the pandemic. This creates quite an interesting set-up. While lucrative pandemic-related sales are on their retreat, Hologic has seen continued growth, bought back shares and maintained balance sheet discipline. All this has gradually pushed down valuations to quite appealing multiples, amidst solid organic growth ...

Investors interested in Medical - Instruments stocks are likely familiar with Hologic (HOLX) and SONOVA HOLDING (SONVY) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes companies with pos ...

Hologic, Inc. (HOLX) recently launched new FDA approved Genius Digital Diagnostics System with the Genius Cervical AI algorithm. The launch marks the first and only FDA-cleared digital cytology system that combines deep-learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells.According to American Cancer Society's most current projection, 4,360 women would lose their lives to invasive cervical cancer in the Unite ...

Hologic (HOLX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this medical device maker have returned -0.7% over the past month versus the Zacks S&P 500 composite's +4.6% change. The Zacks Medical - Instruments industry, to which Hologic belongs, has gained 3.9% over this period. Now the key question is: Where could the stock be headed in the near term?Although media ...

Hologic, Inc. (HOLX) reported adjusted earnings per share (EPS) of 98 cents in first-quarter fiscal 2024, down 8.4% year over year. The bottom line surpassed the Zacks Consensus Estimate by 3.2%.The adjustments include charges and benefits related to the amortization of acquired intangible assets, restructuring and integration/consolidation costs, product line discontinuation and many others.The company’s GAAP EPS were $1.03 in the quarter compared with the year-ago quarter’s EPS of 75 cents, up 37.3%.Reven ...

Hologic, Inc. (NASDAQ:HOLX) Q1 2024 Earnings Conference Call February 1, 2024 4:30 PM ET Company Participants Ryan Simon - Vice President, Investor Relations Steve MacMillan - Chairman, President and Chief Executive Officer Karleen Oberton - Chief Financial Officer Essex Mitchell - Chief Operating Officer Conference Call Participants Tejas Savant - Morgan Stanley Patrick Donnelly - Citi Jack Meehan - Nephron Research John Sourbeer - UBS Vijay Kumar - Evercore ISI Puneet Souda - Leerink Ryan Zimmerman - BTIG ...

Hologic (HOLX) reported $1.01 billion in revenue for the quarter ended December 2023, representing a year-over-year decline of 5.7%. EPS of $0.98 for the same period compares to $1.07 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $983.25 million, representing a surprise of +3.04%. The company delivered an EPS surprise of +3.16%, with the consensus EPS estimate being $0.95.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...